Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.
Pharvaris Trading Down 2.3 %
Pharvaris stock traded down $0.34 during midday trading on Friday, hitting $14.28. The stock had a trading volume of 19,107 shares, compared to its average volume of 72,079. Pharvaris has a 52-week low of $13.48 and a 52-week high of $25.50. The company has a market capitalization of $746.70 million, a PE ratio of -5.10 and a beta of -2.84. The firm's fifty day moving average is $16.31 and its two-hundred day moving average is $18.70.
Wall Street Analyst Weigh In
Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.
Get Our Latest Analysis on Pharvaris
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
